BLOOD GLUCOSE MONITOR ADVERSE INCIDENT REPORTS NEED COMPREHENSIVE ANALYSIS TO DETERMINE IF PUBLIC HEALTH PROBLEM EXISTS, ADVISORY COMMITTEE MEMBERS SAY
This article was originally published in The Gray Sheet
Executive Summary
Self-monitoring blood glucose system manufacturers and FDA need to do additional evaluation of adverse event reports on SMBG systems to get a better sense of the actual level of malfunction, misuse and risk associated with the devices, members of the Clinical Chemistry and Clinical Toxicology Devices Panel recommended at a March 20-21 meeting in Gaithersburg, Maryland.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.